The WHO estimates the average medication adherence rate is 50% in developed nations, though the U.S. trails other countries in reported adherence on Medisafe.…

Shire

Hemophilia newcomer Bioverativ aims to keep parent Biogen's 'patient-centric' corporate image

What'd you miss at J.P. Morgan? Everything you need to know, all in one place

Shire to fork over $350M to settle 'flagrant' Dermagraft kickback claims

Bioverativ remind you of Baxalta? Get ready for a different M&A outcome, execs say

Shire starting on $400M biologics plant that will add 400 jobs

Pharma shares shear Paulson's hedge funds deeply

Shire's new Baxalta hemophilia meds drop the ball in first combined quarter

Allergan’s multidose Restasis nabs FDA approval, heads to battle with Shire’s Xiidra